Posted by Michael Wonder on 28 Jun 2021
SNDX-5613 granted FDA fast track designation for the treatment of relapsed/refractory acute leukemias
28 June 2021 - Syndax Pharmaceuticals today announced that the U.S. FDA has granted fast track designation to SNDX-5613 for the treatment of adult and paediatric patients with relapsed or refractory acute leukemias harbouring a mixed lineage leukaemia rearranged or nucleophosmin mutation.
SNDX-5613 is the Company's highly selective, oral menin inhibitor.
